Development
Cytokinetics, Incorporated
CYTK
$36.16
-$0.42-1.15%
NASDAQ
12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
---|---|---|---|---|---|
Revenue | 1.67M | 378.00K | 867.00K | 4.61M | 1.96M |
Total Other Revenue | -- | -- | -- | -- | 0.00 |
Total Revenue | 1.67M | 378.00K | 867.00K | 4.61M | 1.96M |
Cost of Revenue | 84.98M | 82.53M | 83.19M | 79.42M | 75.02M |
Gross Profit | -83.30M | -82.15M | -82.33M | -74.81M | -73.06M |
SG&A Expenses | 44.11M | 40.11M | 39.72M | 49.67M | 53.97M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 129.09M | 122.64M | 122.92M | 129.09M | 128.99M |
Operating Income | -127.42M | -122.27M | -122.05M | -124.47M | -127.03M |
Income Before Tax | -136.90M | -129.42M | -128.64M | -131.29M | -137.38M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -136.90M | -129.42M | -128.64M | -131.29M | -137.38M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -136.90M | -129.42M | -128.64M | -131.29M | -137.38M |
EBIT | -127.42M | -122.27M | -122.05M | -124.47M | -127.03M |
EBITDA | -121.08M | -120.41M | -120.19M | -122.63M | -125.37M |
EPS Basic | -1.38 | -1.35 | -1.34 | -1.38 | -1.45 |
Normalized Basic EPS | -0.86 | -0.84 | -0.84 | -0.86 | -0.91 |
EPS Diluted | -1.38 | -1.35 | -1.34 | -1.38 | -1.45 |
Normalized Diluted EPS | -0.86 | -0.84 | -0.84 | -0.86 | -0.91 |
Average Basic Shares Outstanding | 99.07M | 96.07M | 95.76M | 95.16M | 94.68M |
Average Diluted Shares Outstanding | 99.07M | 96.07M | 95.76M | 95.16M | 94.68M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |